What is the schedule classification of Spravato (esketamine)?

Spravato (esketamine) is classified as a Schedule III drug. This designation indicates that it has a potential for abuse, but that potential is lower compared to drugs classified as Schedule I or II. Schedule III substances are recognized for having accepted medical uses and can be prescribed by healthcare providers, subject to certain regulations.

Esketamine is a form of ketamine, which is an anesthetic that also has antidepressant properties. The classification reflects the understanding that while it can be misused, particularly in certain contexts, it also serves an important role in treating specific conditions, notably treatment-resistant depression. The Schedule III classification allows for more accessible use in clinical settings while still imposing legal regulations that govern its distribution and use, such as prescription requirements. This classification is crucial in balancing patient access to therapy and the need to control and monitor substances that could be abused.